Drug Safety Diligence Demands Proactive, Ongoing Assessment – FDLI Panel
Executive Summary
To stay afloat with heightened and still-evolving drug safety standards, drug firms must investigate their products for safety signals even in the absence of any indication of a problem, according to a panel at an April 22 conference of the Food & Drug Law Institute